Abstract
Fifteen Alzheimer (AD) and fifteen normative (NM) age-matched autopsy brains were analyzed in superior temporal cortex, hippocampal and brainstem samples. Vascular endothelial growth factor (VEGF) positive capillaries were quantitatively analyzed in all three sites in the 30 cases. Amyloid β42 senile plaques and VEGF positive capillaries were counted and statistically analyzed using Mann-Whitney, Kruskal–Wallis and the non-parametric Spearman’s test. There is a significantly different expression of capillary VEGF between normative and Alzheimer brains. Within Alzheimer’s superior temporal, hippocampus and brainstem sites there was reduced VEGF expression, with the P value being less than 0.05 in all three sites (superior temporal less than 0.035, hippocampus less than 0.001, brainstem less than 0.006). As VEGF is an important endothelial growth factor involved in vascular remodeling, angiogenesis, and endothelial/blood brain barrier maintenance, its reduced expression in Alzheimer’s disease is evidence for altered capillary function in this disease, which may be contributory to its pathogenesis by altering beta amyloid handling and efflux.
Keywords: Alzheimer's disease, blood-brain barrier, senile plaques, VEGF.
Current Neurovascular Research
Title:Reduction in Vascular Endothelial Growth Factor Expression in the Superior Temporal, Hippocampal, and Brainstem Regions in Alzheimer`s Disease
Volume: 11 Issue: 3
Author(s): John Provias and Brian Jeynes
Affiliation:
Keywords: Alzheimer's disease, blood-brain barrier, senile plaques, VEGF.
Abstract: Fifteen Alzheimer (AD) and fifteen normative (NM) age-matched autopsy brains were analyzed in superior temporal cortex, hippocampal and brainstem samples. Vascular endothelial growth factor (VEGF) positive capillaries were quantitatively analyzed in all three sites in the 30 cases. Amyloid β42 senile plaques and VEGF positive capillaries were counted and statistically analyzed using Mann-Whitney, Kruskal–Wallis and the non-parametric Spearman’s test. There is a significantly different expression of capillary VEGF between normative and Alzheimer brains. Within Alzheimer’s superior temporal, hippocampus and brainstem sites there was reduced VEGF expression, with the P value being less than 0.05 in all three sites (superior temporal less than 0.035, hippocampus less than 0.001, brainstem less than 0.006). As VEGF is an important endothelial growth factor involved in vascular remodeling, angiogenesis, and endothelial/blood brain barrier maintenance, its reduced expression in Alzheimer’s disease is evidence for altered capillary function in this disease, which may be contributory to its pathogenesis by altering beta amyloid handling and efflux.
Export Options
About this article
Cite this article as:
Provias John and Jeynes Brian, Reduction in Vascular Endothelial Growth Factor Expression in the Superior Temporal, Hippocampal, and Brainstem Regions in Alzheimer`s Disease, Current Neurovascular Research 2014; 11 (3) . https://dx.doi.org/10.2174/1567202611666140520122316
DOI https://dx.doi.org/10.2174/1567202611666140520122316 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oligomers on the Brain: the Emerging Role of Soluble Protein Aggregates in Neurodegeneration.
Protein & Peptide Letters Programming Apoptosis and Autophagy with Novel Approaches for Diabetes Mellitus
Current Neurovascular Research Therapeutic Nucleic Acids
Recent Patents on Regenerative Medicine Plants Indicated by Brazilian Indians for Disturbances of the Central Nervous System: A Bibliographical Survey
Central Nervous System Agents in Medicinal Chemistry Scutellarin Attenuates Microglia-Mediated Neuroinflammation and Promotes Astrogliosis in Cerebral Ischemia - A Therapeutic Consideration
Current Medicinal Chemistry HHT in Childhood: Screening for Special Patients
Current Pharmaceutical Design Cognitive, Psychological and Psychiatric Effects of Ionizing Radiation Exposure
Current Medicinal Chemistry Neuropsychological Consequences of HIV and Substance Abuse: A Literature Review and Implications for Treatment and Future Research
Current Drug Abuse Reviews Histone Post-translational Modifications to Target Memory-related Diseases
Current Pharmaceutical Design Conference Report: The Myriad Pathways of Neurodegeneration Discussed at NEUROCON 2015
Current Aging Science Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders
Current Pharmaceutical Design Measuring Alzheimer Disease Progression with Transition Probabilities: Estimates from NACC-UDS
Current Alzheimer Research Metabolic Syndrome, Mild Cognitive Impairment and Dementia
Current Alzheimer Research The Many Neuroprogressive Actions of Tryptophan Catabolites (TRYCATs) that may be Associated with the Pathophysiology of Neuro-Immune Disorders
Current Pharmaceutical Design Influence of Statin Use on Endothelial Function: From Bench to Clinics
Current Pharmaceutical Design Assessment of Persistent, Bioaccumulative and Toxic Organic Environmental Pollutants in Liver and Adipose Tissue of Alzheimer’s Disease Patients and Age-matched Controls
Current Alzheimer Research Neuroinflamm-Aging and Neurodegenerative Diseases: An Overview
CNS & Neurological Disorders - Drug Targets The Renin-Angiotensin System and the Neurodegenerative Diseases: A Brief Review
Protein & Peptide Letters Early Life Stress and Epigenetics in Late-onset Alzheimer’s Dementia: A Systematic Review
Current Genomics Association of Amyloid Burden, Brain Atrophy and Memory Deficits in Aged Apolipoprotein ε4 Mice
Current Alzheimer Research